Events and Presentations
The Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting
Matej Ondrus, M.D., Senior Medical Director at Immunic, will present interim data from Immunic’s phase 2 CALLIPER trial of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838).
- Poster Title: Impact of Vidofludimus Calcium on Serum Neurofilament in Progressive MS: Assessment from the CALLIPER Interim Analysis
- Abstract ID: 9651
- Poster Session Date: Thursday, May 30, 2024
- Poster Session Time: 5:15 - 7:15 pm CDT (6:15 - 8:15 pm EDT)
